Allogeneic car-t cell therapies and manufacture thereof

By genetically modifying T cells to reduce or eliminate HLA-A, CIITA, and TRAC expression, the engineered cells overcome immune rejection challenges, enhancing the safety and efficacy of allogeneic CAR T cell therapies.

WO2025049631A1PCT designated stage expired Publication Date: 2025-03-06KYVERNA THERAPEUTICS INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/044268
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-09
Filing Date
2024-08-28
Publication Date
2025-03-06

Smart Images

  • Figure US2024044268_06032025_PF_FP_ABST
    Figure US2024044268_06032025_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are engineered T cells expressing a heterologous chimeric antigen receptor (CAR) and deficient in certain T cell receptor (TCR) and major histocompatibility complex (MHC) genes, useful for allogeneic CAR T cell therapy. Also provided are methods of producing such engineered T cells.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Chimeric antigen receptors targeting CD-19

    US20170107286A1

  • Targeted disruption of t cell and / or HLA receptors

    US20180362926A1

  • Compositions and Methods for Immunotherapy

    US20210340530A1

  • KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS

    US20220251505A1

  • Compositions and methods for genetically modifying ciita in a cell

    WO2022140587A1